ArticleCell biochemistry and biophysics2026
Comparative Evaluation of Antiaging Potential of Cymbopogon Citratus Conjugated Silver Nanoparticles and Citral Against D-galactose Induced Aging in Mice.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Aging and age-associated disorders are a major global concern leading to morbidity and mortality. A key player is oxidative stress arising from excessive reactive oxygen species, which accelerates cellular damage and functional decline. Phytochemicals with antioxidant properties represent promising candidates for anti-aging interventions. This study intended to elucidate the antiaging potential of Cymbopogon citratus against D-galactose induced aging in mice. In vitro antioxidant activity of Cymbopogon citratus extract (CCE), Cymbopogon citratus-loaded silver nanoparticles (CCE AgNPs) and Citral was measured by Total Phenolic content (TPC), Ferric Reducing Antioxidant Power (FRAP), 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS assay), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay. In vitro assays showed dose-dependent increase in all groups with extract consistently exhibiting the strongest reducing capacity, followed by CCE AgNPs and Citral. For in vivo study, a dose of D-galactose (250 mg/kg) was administered by the intraperitoneal route at a volume of 0.2 mL daily for a continuous 60-days period to establish an aging mice model. Different doses of CCE (100, 150, 250 mg/Kg), CCE AgNPs (50,100,200 mg/Kg), and Citral (50,100,150 mg/Kg) were subsequently assessed through a range of biochemical assays. Animals were divided into 12 groups, including normal control, D-gal control, CCE-treated groups (100, 150, and 250 mg/kg), groups treated with CCE AgNPs (50, 100, and 200 mg/kg), groups treated with Citral (50, 100, and 200 mg/kg), and a metformin group (150 mg/kg). Treatments were given orally for 30 consecutive days following D-gal induction. The biochemical analysis showed a dose-dependent increase/decrease in biomarkers with highest dose of each treatment group showing the most pronounced effect. Of all the treatment groups, CCE AgNPs showed the maximum efficacy at dose 200 mg/kg resulting in peak values of CAT (117.8 ± 4.8 U/mL), SOD (89.0 ± 3.8 U/mL), GPx (35.6 ± 1.7 U/mL), GRx (30.2 ± 1.3 U/mL). Also, decrease in MDA (5.2 ± 0.2 nmol/mL), FSH (6.9 ± 0.4 ng/mL) and cortisol (90.5 ± 3.4 ng/mL) demonstrated that AgNPs of Cymbopogon citratus have significant antiaging potential.
Indexed as
Identifiers
41803530What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.